Insulet - PODD Stock Forecast, Price & News

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PODD. Morgan Stanley upped their price objective on shares of Insulet from $244.00 to $273.00 and gave the stock an "equal weight" rating in a report on Monday. Raymond James raised their price target on Insulet from $262.00 to $280.00 in a research report on Friday, August 5th. BTIG Research boosted their price objective on Insulet to $285.00 in a research report on Tuesday. Piper Sandler raised their target price on Insulet from $230.00 to $235.00 and gave the company a "neutral" rating in a report on Friday, August 5th. Finally, Canaccord Genuity Group upped their price target on Insulet from $250.00 to $290.00 and gave the stock a "buy" rating in a report on Friday, August 5th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $295.23.

Insulet Price Performance

Shares of Insulet stock traded up $3.81 during trading on Wednesday, hitting $262.49. 268,972 shares of the company's stock traded hands, compared to its average volume of 570,477. Insulet has a twelve month low of $181.00 and a twelve month high of $324.81. The company has a debt-to-equity ratio of 3.11, a current ratio of 5.98 and a quick ratio of 4.51. The company has a market cap of $18.20 billion, a PE ratio of 524.76 and a beta of 0.73. The firm's fifty day moving average price is $228.52 and its 200 day moving average price is $236.24.

Insulet (NASDAQ:PODD - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The medical instruments supplier reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.72). The company had revenue of $299.40 million for the quarter, compared to analyst estimates of $290.87 million. Insulet had a net margin of 2.94% and a return on equity of 13.29%. The firm's revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 earnings per share. Analysts forecast that Insulet will post 1.3 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Shacey Petrovic sold 15,000 shares of the business's stock in a transaction on Friday, July 1st. The shares were sold at an average price of $222.90, for a total value of $3,343,500.00. Following the sale, the director now owns 13,695 shares in the company, valued at approximately $3,052,615.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Shacey Petrovic sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $222.90, for a total transaction of $3,343,500.00. Following the completion of the sale, the director now owns 13,695 shares of the company's stock, valued at $3,052,615.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Charles Alpuche sold 6,000 shares of the business's stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $215.32, for a total value of $1,291,920.00. Following the completion of the transaction, the chief operating officer now directly owns 43,899 shares in the company, valued at $9,452,332.68. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company's stock.